Article

Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomized rats.

First Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, Tokyo, Japan.
Journal of Oral and Maxillofacial Surgery (Impact Factor: 1.33). 05/2003; 61(4):471-80. DOI: 10.1053/joms.2003.50093
Source: PubMed

ABSTRACT This study investigated the effect of parathyroid hormone (1-34) [PTH(1-34)] on bone reactions after tibial placement of titanium screw implants into ovariectomized rats.
Twelve-week-old female Wistar rats were divided into 3 groups of 24. The first group (Sham group) was sham-operated; the second group (OVX group) was ovariectomized only; and the third group (PTH group) was subcutaneously administered 30 microg/kg PTH in the dorsal region 3 days per week starting the fourth week after ovariectomy until the end of the experiment. Titanium screw implants were placed in the proximal metaphysis of the tibia of all 3 groups at 168 days after surgery. The animals were killed 7, 14, 28, and 56 days after implantation. Undecalcified sections were prepared and evaluated by light microscopy. Histomorphometric measurements were obtained using a computer-based image analyzer to quantify the unit bone mass around the implant and the rate of implant-bone contact.
When PTH administration was started 21 days after ovariectomy, the volume density of bone around implants in the PTH group was almost the same as that of the Sham group throughout the entire observation period. This finding suggests that not only can intermittent human PTH(1-34) administration prevent resorption of newly generated trabeculae around an implant but also it can aid in the recovery of bone volume lost due to ovariectomy.
When dental implants are applied to jaw bone showing trabecular bone loss, it may be possible to increase bone density around an implant by intermittent human PTH(1-34) administration and thereby improve clinical results.

0 Bookmarks
 · 
51 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study was designed to compare the effects of alendronate (ALN), strontium ranelate (SR), and zoledronic acid (ZOL) on bone-implant osseointegration in ovariectomized rats. Histological examination and biomechanical tests show that ZOL, ALN, and SR enhance bone-implant osseointegration; ALN and SR have similar effects, while ZOL enhances bone-implant osseointegration more than ALN and SR INTRODUCTION: This study aims to compare the effects of ALN, SR, and ZOL on bone-implant osseointegration in ovariectomized rats. METHODS: Sixty female Sprague-Dawley rats were included in this study. Of them, 48 rats were ovariectomized (OVX) and assigned to four groups: OVX (OVX + Veh), ALN (OVX + ALN), SR (OVX + SR), and ZOL (OVX + ZOL). And another 12 rats were sham-operated as a control group (Sham). Four weeks after ovariectomy, HA-coated titanium implants were inserted into the tibias bilaterally in all rats. Then the rats in groups ALN, SR, and ZOL were systemically administrated with alendronate (7 mg/kg/week, orally), strontium ranelate (500 mg/kg/day, orally), or a single injection of zoledronic acid (0.1 mg/kg, iv), respectively. Twelve weeks after implantation, all rats were sacrificed to get the femurs and tibias. Histological examination and biomechanical tests were used to evaluate bone-implant osseointegration in all groups. RESULTS: ALN, SR, and ZOL significantly increased distal femoral BMD when compared with group OVX; ZOL increased BMD significantly more than ALN and SR (P < 0.05). Significant increase of bone-to-implant contact and peri-implant bone fraction were observed in groups ALN, SR, and ZOL when compared with group OVX (P < 0.05). Groups ALN and SR were inferior to groups ZOL and Sham (P < 0.05) in bone-to-implant contact and peri-implant bone fraction. Similar results were found in biomechanical testing (max pushout force). CONCLUSIONS: In rats losing bone rapidly after ovariectomy, systemic administration of ZOL, ALN, and SR causes better bone-implant osseointegration when compared to OVX; ALN and SR have similar positive effects on osseointegration, while ZOL, that was given in a dose with more positive BMD effect than that of ALN or SR, causes better osseointegration than either ALN or SR.
    Osteoporosis International 02/2013; · 4.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: The aim of this study is to compare the osseointegration behavior of titanium (Ti) and titanium-zirconium (TiZr) implants in ovariectomized (OVX) rabbits. MATERIALS AND METHODS: Twelve ovariectomized New Zealand rabbits submitted to a hypocalcic diet and 12 sham-aged rabbits were used. After the bone mass loss induction period, TiZr or Ti implants both benefiting from a SLActive surface treatment were randomly inserted in the tibia and femur of each animal. The total of 24 rabbits were divided in four groups (n = 6): SHAM + Ti, OVX + Ti, SHAM + TiZr,OVX + TiZr. The animals were respectively sacrificed 3 and 6 weeks after dental implant placement. Six implants in each group at each time point were subjected to removal torque testing, and the remaining implants were prepared for histomorphometric analysis. RESULTS: At the end of the healing period, all implants were osseointegrated. The removal torque value of the SHAM-TiZr group was significantly higher than those of the SHAM-Ti group (P < 0.001). The removal torque of the OVX-Ti group was significantly lower than those of the OVX-TiZr group. All groups demonstrated an increase in the peak torque value after 6 weeks: 46.0 and 50.8 Ncm for the OVX and the SHAM animals, respectively, in the case where Ti implants were used. When TiZr implants were inserted, the values reached 60.7 and 76.2 Ncm with a similar group configuration. The BIC and the BA/TA analysis showed an increase between week 3 and 6 in the case of nonovariectomized animals. From week 3 to 6, the BIC went from 37.1 ± 14.3 to 47.7 ± 8.7 for the SHAM + Ti group and from 37.6 ± 10.9 to 50.4 ± 11 for the SHAM + TiZr group. The BIC values were not significantly different between groups. CONCLUSION: The parameters intended to be representative of the bone morphology (BIC & BATA) did not help to discriminate between Ti and TiZr which appeared to behave similarly in this experimental model. However, the removal torque values for the TiZr group were statistically higher than those of the Ti group in both the SHAM and the ovariectomized animals. That likely reflected an increased quality of bone around the TiZr implants.
    Clinical Oral Implants Research 02/2013; · 3.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of human parathyroid hormone 1-34 (PTH) and zoledronic acid (ZA) alone or in combination on bone healing in osteoporotic settings was tested using implants inserted in tibiae of ovariectomized (OVX) rats. Combination therapy promoted bone healing more than each treatment alone 12 weeks after implant insertion. INTRODUCTION: PTH and ZA have been demonstrated to be effective on implant fixation. However, reports about the combined use of PTH and ZA for promotion of bone healing around implant in osteoporotic settings are still limited. This study aims to investigate effects of PTH+ZA on implant stabilization in OVX rats. METHODS: Twelve weeks after bilateral ovariectomy, OVX rats randomly received implants without or with ZA (by immersion in 1 mg/ml ZA solution for 24 h). Subsequently, half of the animals from each group also received subcutaneous injections of PTH (60 μg/kg, three times a week) for 12 weeks. Thus, there were four groups: control, PTH, ZA, and PTH+ZA. RESULTS: All treatments promoted bone healing around implant compared to control, but PTH+ZA treatment showed significantly stronger effects than PTH or ZA alone in histological, micro-CT, and biomechanical tests. CONCLUSION: The results indicated the additive effects of PTH and ZA on implant fixation in OVX rats; it was suggested that the anabolic effect of PTH was potent and not blunted by ZA during bone healing around implant when used concurrently.
    Osteoporosis International 01/2013; · 4.04 Impact Factor